Stock Financial Ratios, Dividends, Split History

THC / Tenet Healthcare Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,435.69
Enterprise Value ($M)17,297.65
Book Value ($M)-147.00
Book Value / Share-1.45
Price / Book-16.54
NCAV ($M)-15,407.00
NCAV / Share-152.38
Price / NCAV-0.16
Income Statement (mra) ($M)
Net Income-320.00
Balance Sheet (mrq) ($M)
Cash & Equivalents611.00
Cash / Share6.04
Quick Ratio1.22
Current Ratio1.29
Share Statistics
Weighted Average Number Of Shares Outstanding Basic100,592,000
Weighted Average Number Of Diluted Shares Outstanding100,592,000
Common Shares Outstanding101,107,955
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.02
Return on Assets (ROA)-0.01
Return on Equity (ROE)-0.77
Identifiers and Descriptors
Central Index Key (CIK)70318
Industry Groups
SIC 8062 - General Medical and Surgical Hospitals
Related CUSIPS
08033G407 88033G907 88033G957

Split History

Stock splits are used by Tenet Healthcare Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Peers - General Medical and Surgical Hospitals (8062)

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN:, Inc Analysis and Research Report

11h - Asif

Overview opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

Related News Stories

Can Universal Health (UHS) Q1 Earnings Beat on Admissions?

2018-04-23 zacks
Universal Health Services, Inc. (UHS - Free Report) is set to report first-quarter 2018 results on Apr 25 after market close. Last quarter, the company delivered a positive earnings surprise of 8.70%. (33-0)

Oakmark Global Fund: Q1 2018

2018-04-23 seekingalpha
The Oakmark Global Fund felt the downtrend’s pull and lost 2.6% in the quarter, which compares to a 1.3% loss for the MSCI World Index and a 1.0% loss for the Lipper Global Fund Index. (243-0)

The 7 Most Undervalued Stocks In Larry Robbins’ Portfolio

2018-03-28 investorplace
Larry Robbins is a hedge fund manager and CEO of Glenview Capital Management. He is also well known for his quarterly letters to investors. (139-0)

Why Is Tenet Healthcare (THC) Up 15% Since Its Last Earnings Report?

2018-03-28 zacks
It has been about a month since the last earnings report for Tenet Healthcare Corporation (THC - Free Report) . Shares have added about 15% in that time frame. (15-0)

Why did Community Health Stock Sink More Than 50% in a Year?

2018-03-21 zacks
Community Health Systems, Inc. (CYH - Free Report) has been losing out on investors’ confidence due to the stock’s persistently poor performance in comparison to the industry as well as its peers. The company’s lower-than-expected volumes, payer rates, increased bad debt, a weak top line combined with higher operating expenses leading to a further drag in the margin have likely caused this underperformance. (42-0)

CUSIP: 88033G407